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room visits was negatively associated with repeat mammography screening. No 
association was observed between county level characteristics such as number of 
primary care physicians, number of mammography screening facilities, and number 
of federally qualified health care centers per 10,000 women and repeat mammog-
raphy screening. ConClusions: Mammography screening is underutilized in the 
Medicaid population. Various factors predicting repeat mammography screening 
were identified. Program planners should consider these factors when designing 
educational interventions aimed at increasing routine use of mammography screen-
ing among Medicaid enrollees.
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ONCOlOgy PriCiNg TreNds iN The UNiTed sTaTes aNd The UNiTed 
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objeCtives: To understand relative price differential for cancer drugs in the U.S. 
and the U.K. Develop implications for pricing strategy and patient access for cancer 
drugs. Methods: Ten branded cancer drugs were selected and their prices for simi-
lar dose and packaging were compared in the U.S. and the U.K. Prices were analyzed 
for the end of 2011 and 2012. Historical exchange rates were used to convert British 
pounds to US dollars. Relative price discount was calculated for all selected cancer 
drugs. KOLs and payers were interviewed to understand current and future implica-
tions of this price differential. Results: The median price discount for selected ten 
branded cancer drugs in the UK versus the United States was ~50%. The range of 
discount for 10 branded cancer drugs was 27%-61%. The price discount for oral small 
molecule drugs was higher than for biologics (55% vs. 45%). Since the U.K. is one of 
the few remaining free pricing markets in Europe, other European markets are likely 
to have even higher discounts relative to the prices in the U.S. Due to rising coinsur-
ance of specialty products, U.S. cancer patients bear significantly higher costs than 
patients in the UK. KOL and payer interviews suggest U.S. pricing trends for cancer 
drugs are unlikely to be sustained at this level in the future. ConClusions: U.S. 
cancer drug prices are significantly higher than the prices in the U.K. This price 
differential is unlikely to be sustained in the future.
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objeCtives: The purpose of this study was to understand pCODR’s impact on pro-
vincial formulary decisions since its establishment in 2010. Methods: 29 pCODR 
reviews were analysed. The agency publishes its reviews on its website, www.pcodr.
ca, including final recommendations for provinces to consider in their respective 
formularies. pCODR also publishes a “Provincial Funding Summary” of 9 provinces 
(all except Québec) following each of its final recommendations when available. 
pCODR’s recommendations were indexed with corresponding provincial decisions 
in order to measure the frequency with and degree to which provinces follow pCODR 
guidance. Results: Out of the 29 final recommendations analysed, pCODR has 
issued 24 positive funding recommendations, including 20 “conditional on cost-
effectiveness being improved.” Given the 24 positive recommendations, provinces 
funded products with similar or more restrictiveness than pCODR’s recommenda-
tion 21.3% of the time and with less restrictiveness 6.9% of the time; provinces 
remained under consideration, negotiation, or lacked any status update 71.8% of 
the time. No province has rejected funding of an oncology product following a 
positive pCODR recommendation. pCODR issued negative funding recommenda-
tions 5 of 29 times. Of these, provinces have almost never funded the product in 
turn. ConClusions: Provinces have tended to follow pCODR’s recommendations 
or not make a decision. Compared to other provinces, Alberta tends to fund prod-
ucts with fewer restrictions than pCODR recommends, while Ontario demonstrates 
more restrictiveness. Saskatchewan has followed pCODR most closely. Manitoba, 
New Brunswick, Newfoundland and Labrador, and Prince Edward Island respond 
most slowly, in “consideration” or “negotiation” of most pCODR recommendations.
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objeCtives: There is limited information on the relationship between insur-
ance coverage and prostate cancer(PCa)-screening practices among race/ethnic 
minorities in ambulatory care settings in the US. The objective of this study was 
to determine whether the observed race/ethnicity differences in prostate-specific 
antigen(PSA)-screening for PCa may be explained by differences in insurance 
coverage. Methods: We analyzed a nationally representative sample of visits to 
office-based physicians’ practices from 2005-2010 using the National Ambulatory 
Medical Care Survey (NAMCS). The sample consisted of outpatient visits for preven-
tive health exams (PHEs) of men aged 40 years and above, without PCa. The primary 
insurance payer categories were mutually exclusive and included the following: 
Medicare, Medicaid, private insurance and other types. Information on the receipt 
of PSA-screening, demographics, physician specialty and type of office setting were 
collected. Generalized estimating equations were used to investigate the effect of 
race and insurance type on PSA-screening. Results: Application of the inclusion 
criteria resulted in 5,829 office-visits for PHEs. Majority (57%) of the sample was aged 
below 66 years, 10% were African Americans and 9% Hispanics. Over 47% were cov-
ered by private insurance, 39% by Medicare and 5% Medicaid. Overall, 16% received 
PSA-screening during a PHE. Hispanics (prevalence ratio:0.62,95%CI:0.43-0.90) and 
Medicaid (prevalence ratio:0.24, 95%CI:0.11-0.55) patients were less likely to receive 
PSA-screening compared to Whites and patients with private insurance. PHEs 
surgery at any time during the study period was present in 94.5%, 91.2%, and 65.9% 
of patients, respectively (5.5% of patients had no claims indicating any prior cancer 
treatment). Mean length of chemotherapy treatment was 806 days, and 571 days for 
biologic treatment. ConClusions: Patients initiated on regorafenib were largely 
suffering from metastatic cancer, and had a range of comorbid conditions. Nearly 
all patients were treated with chemotherapy and/or biologic agents before initiat-
ing regorafenib treatment.
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objeCtives: Guidelines on the management of cancer treatment-induced bone 
loss (CTIBL) in men receiving androgen deprivation therapy (ADT) for prostate can-
cer (PC) recommend bisphosphonate (BP) therapy or other bone-modifying agents 
(BMAs). There is limited information on the use of BMAs for CTIBL in men with PC. 
We examined BMA utilization patterns following ADT initiation among elderly men 
with non-metastatic PC. Methods: Using linked Surveillance, Epidemiology, and 
End Results (SEER) & Medicare data, we identified men aged 66+ with incident non-
metastatic PC diagnosed during 2007-2009, with claims from 2006-2010. Patients 
received ADT within 6 months after diagnosis and had at least 6 months of Part D 
enrollment during follow-up. Multivariable logistic regression model was estimated 
to identify demographic and clinical factors associated with BMA utilization fol-
lowing ADT initiation. Results: We identified 7,545 non-metastatic PC patients 
who received ADT (median age: 74). The sample included patients with stage 2 
(80%), 3 or 4 (8%), or unstaged (12%) PC. Overall, 8.6% had any BMA use after ADT 
initiation and the most common BMAs were oral BP (5.2%), intravenous BP (3.3%), 
followed by calcitonin (0.5%). A small proportion (1.6%) of the sample had any BMA 
use prior to ADT initiation. The median time to first BMA use after ADT initiation 
was 189 days. Factors associated with statistically significant increased likelihood 
of BMA use were older age, poorly differentiated tumor, and presence of osteo-
porosis. Compared to stage 2 PC patients, those with stages 3 or 4, and unstaged 
PC were more likely to receive BMA (p< 0.01). Patient race/ethnicity, comorbidity 
profile, and history of fracture were not statistically significantly associated with 
BMA receipt. ConClusions: Less than 10% of elderly men diagnosed with non-
metastatic PC and initiating ADT received any BMA, suggesting that a significant 
gap remains in the prevention and treatment of CTIBL in this population.
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objeCtives: Quantify the price, time and volume concessions incurred by manu-
facturers launching new oncology drug treatments across the EU5 in order to gain 
market access Methods: We analyzed launches of innovative oncology products 
in both the US and EU5 since 2005 (n= 23). Two cohorts (2005-08; 2009-2013) were 
defined where we analyzed price, volume and access time. We created an overall 
opportunity index combining these 3 variables. Prices (MSP – Midas) were made rela-
tive to the US price. Time to access: 2 points were measured – time from regulatory 
approval to price approval by authorities where applicable and time to first reported 
sales. Volume was assessed as units sold over the period cohort, normalized by the 
local epidemiology Results: Price, time to access and volume are all worsening 
for all EU markets compared to the US. The overall combined opportunity index has 
declined or remained low and flat in France (1.22 – 0.93), Germany (0.80 – 0.75), Italy 
(0.45 – 0.46), Spain (0.67 – 0.39) and UK (0.54 – 0.57). US = 1. ConClusions: Ongoing 
EU health care budget management have been modifying the relative commercial 
attractiveness compared to the US of many products including new oncology com-
pounds in Europe. The EU empirical mindset of trading off price to gain faster access 
to market with no or minimal concession on the usage is not supported by the data. 
For a health care perspective, the under usage of oncology products potentially and 
directly impacting overall survival of the patient compared to the US may potentially 
lead to a lower survival in EU compared to the US. Epidemiologists may only able to 
detect this consequence in the coming years.
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objeCtives: Limited information currently exists regarding use of routine mam-
mography screening among Medicaid enrollees. The current study determined 
the prevalence of repeat mammography screening and the associated factors in 
the Medicaid population. Methods: The 2006-2008 Medicaid Analytic Extract 
(MAX) data for 39 states in the United States were used in this study. The target 
population consisted of female recipients aged 40-64 years who were continuously 
enrolled in the Medicaid program during 2006-2008. Recipients with a diagnosis 
of breast cancer were excluded from the study. Repeat mammography screening 
was defined as receipt of two successive mammograms during the study period 
with a gap of 10-14 months. The effect of various recipient- and county-level fac-
tors on repeat mammography screening was determined using hierarchical logistic 
regression. Results: Approximately 1.19% of the recipients received repeat mam-
mograms during the study period. The repeat mammography screening rates were 
higher in older women and those belonging to ethnic minorities than younger 
women and whites. Number of visits to physician offices and outpatient centers, 
hormone replacement therapy, and routine cervical cancer screening were positively 
associated with repeat mammography screening. However, number of emergency 
